Patents by Inventor Mark Lautens

Mark Lautens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOTHIAZOLE COMPOUNDS AND ANALOGS THEREOF AND METHODS FOR TREATING NEMATODE INFECTIONS IN PLANTS
    Publication number: 20240109914
    Abstract: The present application relates to the treatment of plant nematode infections. For example, the application relates to the use of one or more compounds of Formula (I) as defined herein, or compositions comprising these compounds, for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection in a plant in need thereof. Also included are novel compounds within the scope of Formula I and compositions and uses of these compounds for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection in a plant in need thereof.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 4, 2024
    Inventors: Andrew Burns, Peter Roy, Rachel Baker, Mark Lautens
  • PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS
    Publication number: 20230339874
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 26, 2023
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Andrew Burns, Rachel Baker, Mark Lautens
  • Compounds and methods for treating nematode infections
    Patent number: 11517568
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 6, 2022
    Assignee: The Governing Council of The University of Toronto
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Andrew Burns, Rachel Ross, Mark Lautens
  • COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS
    Publication number: 20220354117
    Abstract: The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection.
    Type: Application
    Filed: September 10, 2019
    Publication date: November 10, 2022
    Inventors: Peter John Roy, Sean Harrington, Andrew Burns, Jacob Edward Pyche, Genna M. Luciani, Jessica Knox, Mark Lautens, Ken Loon Choo
  • Compounds and methods for treating nematode infections
    Patent number: 11364234
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 21, 2022
    Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
  • COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS
    Publication number: 20200405710
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Andrew Burns, Rachel Ross, Mark Lautens
  • Novel compounds and a novel process for their preparation
    Publication number: 20080300271
    Abstract: The present invention is directed to a procedure for making an enantidimerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nuclophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Application
    Filed: July 28, 2008
    Publication date: December 4, 2008
    Inventors: Keith Fagnou, Mark Lautens
  • Compounds and a novel process for their preparation
    Patent number: 7420003
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: September 2, 2008
    Assignee: Astrazeneca AB
    Inventors: Keith Fagnou, Mark Lautens
  • Screening Methods
    Publication number: 20080039625
    Abstract: Disclosed are processes for the preparation of 2-substituted indole compounds wherein the 2-substituent comprises an R4 group, wherein R4 is selected from the group consisting of monocyclic aromatic, polycyclic aromatic, monocyclic heteroaromatic, polycyclic heteroaromatic, 1° alkyl, and alkenyl, all of which are optionally substituted at one or more substitutable positions with one or more suitable substituents, and wherein R4 is bonded to the 2-position of the indole ring via a C—C bond; the process comprising reacting an orthogem-dihalovinylaniline compound of the formula (I): wherein Halo comprises Br, Cl, or I; each of the one or more R1 is independently selected from the group consisting of H, fluoro, lower alkyl, lower alkenyl, lower alkoxy, aryloxy, lower haloalkyl, lower alkenyl, —C(O)O-lower alkyl, monocyclic or polycyclic aryl or heteroaryl moiety, or R1 is an alkenyl group bonded so to as to form a 4- to 20-membered fused monocycle or polycyclic ring with the indole ring; all of which are optional
    Type: Application
    Filed: November 4, 2005
    Publication date: February 14, 2008
    Inventors: Mark Lautens, Yuanqing Fang
  • Novel compounds and a novel process for their preparation
    Publication number: 20050014721
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Application
    Filed: May 28, 2004
    Publication date: January 20, 2005
    Inventors: Keith Fagnou, Mark Lautens
  • Compound and a novel process for their preparation
    Patent number: 6784210
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: August 31, 2004
    Assignee: AstraZeneca AB
    Inventors: Keith Fagnou, Mark Lautens
  • Novel compounds and a novel process for their preparation
    Publication number: 20030144275
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Application
    Filed: December 12, 2002
    Publication date: July 31, 2003
    Applicant: AstraZeneca AB
    Inventors: Keith Fagnou, Mark Lautens
  • Hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand
    Patent number: 6525068
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: February 25, 2003
    Assignee: AstraZeneca AB
    Inventors: Keith Fagnou, Mark Lautens